Chemokine Cxcl9 attenuates liver fibrosis-associated angiogenesis in mice

Hepatology

Volumn 55, Issue 5, 2012, Pages 1610-1619

  Sahin, Hacer ^a   Borkham Kamphorst, Erawan ^a   Kuppe, Christoph ^a   Zaldivar, Mirko Moreno ^a   Grouls, Christoph ^a   Al samman, Muhammad ^a   Nellen, Andreas ^a   Schmitz, Petra ^a   Heinrichs, Daniel ^a   Berres, Marie Luise ^a   Doleschel, Dennis ^a   Scholten, David ^a   Weiskirchen, Ralf ^a   Moeller, Marcus J ^a   Kiessling, Fabian ^a   Trautwein, Christian ^a   Wasmuth, Hermann E ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOGENESIS INHIBITOR; ANTIFIBROTIC AGENT; CARBON TETRACHLORIDE; CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GASTROINTESTINAL AGENT; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE C GAMMA; RECOMBINANT CXCL9 CHEMOKINE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIFIBROTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; FIBROGENESIS; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LIVER FIBROSIS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STELLATE CELL; WILD TYPE;

ANALYSIS OF VARIANCE; ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CXCL9; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; HEPATOCYTES; INTERFERON-GAMMA; LIVER CIRRHOSIS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; RANDOM ALLOCATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84859969340     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25545     Document Type: Article

References (33)

1. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-1669.
2. Corpechot C, Barbu V, Wendum D, Kinnman N, Rey C, Poupon R, et al. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. HEPATOLOGY 2002; 35: 1010-1021.
3. Medina J, Arroyo AG, Sanchez-Madrid F, Moreno-Otero R. Angiogenesis in chronic inflammatory liver disease. HEPATOLOGY 2004; 39: 1185-1195.
4. Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis. HEPATOLOGY 2010; 51: 1445-1449.
5. Keeley EC, Mehrad B, Strieter RM. Chemokines as mediators of neovascularization. Arterioscler Thromb Vasc Biol 2008; 28: 1928-1936.
6. Sahin H, Trautwein C, Wasmuth HE. Functional role of chemokines in liver disease models. Nat Rev Gastroenterol Hepatol 2010; 7: 682-690.
7. Wasmuth HE, Lammert F, Zaldivar MM, Weiskirchen R, Hellerbrand C, Scholten D, et al. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology 2009; 137: 309-319, 319 e301-303.
8. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004; 4: 583-594.
9. Schrage A, Wechsung K, Neumann K, Schumann M, Schulzke JD, Engelhardt B, et al. Enhanced T cell transmigration across the murine liver sinusoidal endothelium is mediated by transcytosis and surface presentation of chemokines. HEPATOLOGY 2008; 48: 1262-1272.
10. Santodomingo-Garzon T, Han J, Le T, Yang Y, Swain MG. Natural killer T cells regulate the homing of chemokine CXC receptor 3-positive regulatory T cells to the liver in mice. HEPATOLOGY 2009; 49: 1267-1276.
11. Erhardt A, Wegscheid C, Claass B, Carambia A, Herkel J, Mittrucker HW, et al. CXCR3 deficiency exacerbates liver disease and abrogates tolerance in a mouse model of immune-mediated hepatitis. J Immunol 2011; 186: 5284-5293.
12. Jiang D, Liang J, Hodge J, Lu B, Zhu Z, Yu S, et al. Regulation of pulmonary fibrosis by chemokine receptor CXCR3. J Clin Invest 2004; 114: 291-299.
13. Nakaya I, Wada T, Furuichi K, Sakai N, Kitagawa K, Yokoyama H, et al. Blockade of IP-10/CXCR3 promotes progressive renal fibrosis. Nephron Exp Nephrol 2007; 107: e12-21.
14. Thabut D, Shah V. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? J Hepatol 2010; 53: 976-980.
15. Fernandez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol 2009; 50: 604-620.
16. Strieter RM, Burdick MD, Gomperts BN, Belperio JA, Keane MP. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 593-609.
17. Sulpice E, Bryckaert M, Lacour J, Contreres JO, Tobelem G. Platelet factor 4 inhibits FGF2-induced endothelial cell proliferation via the extracellular signal-regulated kinase pathway but not by the phosphatidylinositol 3-kinase pathway. Blood 2002; 100: 3087-3094.
18. Keane MP, Belperio JA, Arenberg DA, Burdick MD, Xu ZJ, Xue YY, et al. IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol 1999; 163: 5686-5692.
19. Hakroush S, Moeller MJ, Theilig F, Kaissling B, Sijmonsma TP, Jugold M, et al. Effects of increased renal tubular vascular endothelial growth factor (VEGF) on fibrosis, cyst formation, and glomerular disease. Am J Pathol 2009; 175: 1883-1895.
20. Berres ML, Koenen RR, Rueland A, Zaldivar MM, Heinrichs D, Sahin H, et al. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest 2010; 120: 4129-4140.
21. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995; 147: 9-19.
22. Taura K, De Minicis S, Seki E, Hatano E, Iwaisako K, Osterreicher CH, et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology 2008; 135: 1729-1738.
23. Campanella GS, Colvin RA, Luster AD. CXCL10 can inhibit endothelial cell proliferation independently of CXCR3. PLoS One 2010; 13; 5: e12700.
24. Wakabayashi Y, Usui Y, Okunuki Y, Kezuka T, Takeuchi M, Goto H, et al. Correlation of vascular endothelial growth factor with chemokines in the vitreous in diabetic retinopathy. Retina 2010; 30: 339-344.
25. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, et al. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 2003; 52: 1347-1354.
26. Lee JS, Semela D, Iredale J, Shah VH. Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte? HEPATOLOGY 2007; 45: 817-825.
27. Sulpice E, Contreres JO, Lacour J, Bryckaert M, Tobelem G. Platelet factor 4 disrupts the intracellular signalling cascade induced by vascular endothelial growth factor by both KDR dependent and independent mechanisms. Eur J Biochem 2004; 271: 3310-3318.
28. Tugues S, Fernandez-Varo G, Munoz-Luque J, Ros J, Arroyo V, Rodes J, et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. HEPATOLOGY 2007; 46: 1919-1926.
29. Shah VH, Bruix J. Antiangiogenic therapy: not just for cancer anymore? HEPATOLOGY 2009; 49: 1066-1068.
30. Patsenker E, Popov Y, Stickel F, Schneider V, Ledermann M, Sagesser H, et al. Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. HEPATOLOGY 2009; 50: 1501-1511.
31. Stockmann C, Kerdiles Y, Nomaksteinsky M, Weidemann A, Takeda N, Doedens A, et al. Loss of myeloid cell-derived vascular endothelial growth factor accelerates fibrosis. Proc Natl Acad Sci U S A 2010; 107: 4329-4334.
32. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. FASEB J 1997; 11: 457-465.
33. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. HEPATOLOGY 2009; 49: 1245-1256.